


Guiding the Evolution to Clinical Data Scientist

Innovation, Certification and Learning Continuity



The industry role evolution

Patrick Nadolny

Head, Global Data Management

sanofi



Our CDS Journey

Internal



The 5Vs of Clinical Data




The evolution of Clinical Data Review



The Automation of CDM Driven Activities

Birth of Clinical Data Science


SCDM New Vision



Evolution Drivers (June-2019)



DCT Topic Brief (April 2020)



Audit Trail Review (April 2021)



Risk-Based CDM



The CDM Role Evolution



The Automation of CDM Driven Activities

4 eSource Topic Briefs
4 Perspectives !! (Sep 2023)

CCDA (Sep 2024)

2019 Refection

2020

2021


2022 Position

2023


Action

2025

Technology Enablers (March-2020)



CDS Portal (April 2020)



Role Evolution (August-2020)

CDS Position Paper (Sep 2022)

New Vision
New Structure

13 eSource Podcasts (Sep 2023)



CCDS (Sep 2025)



elev8

Complex Protocols

Risk based CDM



Decentralized Clinical Trials

Artificial Intelligence

Clinical Data Science Evolution Drivers

Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry

DRAFT

This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register or to the offices managing the availability of the draft guidance document. All comments should be submitted with the subject line "Comments on Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials Guidance for Industry".

For questions regarding this draft document, contact (CDER) Office of Biostatistics, 340-462-4020, or (CDER) Office of New Drugs, 340-462-4020, or (CDER) Office of Clinical Research and Biostatistics, 340-462-4020, or (CDER) Office of Minority Health and Health Equity (OMH), 340-462-4020, or (CDER) Office of Clinical Medical, 340-462-4020.

Apr 2022

FDA

Digital Health Technologies for Remote Data Acquisition in Clinical Investigations Guidance for Industry, Investigators, and Other Stakeholders

Dec 2023

FDA

Master Protocols for Drug and Biological Product Development Guidance for Industry

DRAFT

This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register or to the offices managing the availability of the draft guidance document. All comments should be submitted with the subject line "Comments on Master Protocols for Drug and Biological Product Development Guidance for Industry".

For questions regarding this draft document, contact (CDER) Office of Biostatistics, 340-462-4020, or (CDER) Office of New Drugs, 340-462-4020, or (CDER) Office of Clinical Research and Biostatistics, 340-462-4020, or (CDER) Office of Minority Health and Health Equity (OMH), 340-462-4020, or (CDER) Office of Clinical Medical, 340-462-4020.

Dec 2023

FDA

Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry

Mar 2022

FDA

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Nov 2019

FDA

ICH E6 (R3) GOOD CLINICAL PRACTICE (GCP)

Jan 2025

FDA

ICH E8 (R1) GENERAL CONSIDERATIONS FOR CLINICAL STUDIES

Nov 2021

FDA

Clinical Trial Diversity

DHT in Clinical Trials

Master Protocols


Adaptive Designs

ICH E6 R3

ICH E8 R1

European DCT Recommendations

Decentralized Clinical Trials



EMA Reflection Paper on the use of AI in the medicinal product lifecycle

EMA Reflection Paper on the use of Artificial Intelligence (AI) in the medicinal product lifecycle

July 2023

FDA

Resiliency to Disruptions

Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies

Guidance for Industry, Investigators, and Institutional Review Boards

This guidance is for immediate implementation.

FDA is issuing this guidance in accordance with section 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA), which permits FDA to issue guidance to assist industry in understanding FDA's current thinking on a topic.

Additional information is available at www.fda.gov. You can also contact the Office of Disasters and Public Health Emergencies at 301-435-4000.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.

Comments should be submitted in accordance with the instructions in the document.


Comments should be submitted in accordance with the instructions in the document.

CDS Evolution Drivers



Decentralized Clinical Trials

Apr 2020



The 5Vs of Clinical Data

Mar 2022



The CDM Role Evolution

Aug 2022



The evolution of Clinical Data Review

Apr 2022



Risk-Based CDM

Jul 2022



eSource
Vendors / CROs,
Sites, Sponsors and Regulators

Sep 2023




CDS Evolution Drivers



The Automation of CDM Driven Activities

June 2022




SCDM

CDM Industry

Competency Framework

CDM  CDS



CCDS Certification



Dr. Deepak Kallubundi
*Executive Director
Global Head of CDM Operations*



Dr. Shobha Muniyappa
*Associate Director
CDM Operations*



Why Is Certification Needed?





Key Benefits of SCDM Certification

- **Validates expertise**- Provides an objective to validate professional knowledge and skills
- **Ensures Data Quality**- Certified Professionals are better equipped to implement best industry practices
- **Enhances professional credibility and career advancement** opportunities
- Demonstrates commitment to **continuous professional development**
- **Sets a Global Standards**- helps establish consistent, global benchmark for excellence and professional discipline

Job Analysis



Job Analysis – What?



- Study of a profession, occupation, or role to identify the *essential job duties* and *essential knowledge and skills* required for *competent* job performance
- Provides relative importance of tasks and knowledge or skills



Job Analysis – Why?



- Content validity
- Legal defensibility

**JOB ANALYSIS =
FOUNDATION FOR
EXAM**





Brief Overview of JA and Exam Development Process



Content Definition and Grouping Meetings



Test Blueprint Finalization



Write and Classify Items



Administer Beta Exam






Determine Passing Score




Job Analysis – How?

- Move to more detailed




JA Step 1: Content Definition and Grouping

- Review the current CCDS body of knowledge, tasks, and other documentation SCDM has developed
- Sort into a structure that can reliably and fairly assess candidates for the CCDS credential



TASK DOMAINS & STATEMENTS


- Identify job domains
- Write task statements for each domain
 - Comprehensive list relative to scope of certification program
 - No overlap or repetition
 - Consistent with purpose and level of credential




TASK STATEMENTS

Each task statement should include:

- **Who** is doing the action? (implied)
- **What** is the action?
- **To whom/what** is the action directed?
- **Why** is the action being done?
- **How** is the action being done?
- **What work products**, if any, result from the action?



JA Step 2: Test Blueprint Finalization



- Goal is to design assessment that will result in **VALID** inferences and **RELIABLE** measurement
- Includes content areas for exam and weights, types of items, how exam will be scored, how scores will be used, etc.





CCDS Domains


CCDS Domain
Risk-Based CDM
Clinical Trial Operations
Regulations & Standards
AI & Cognitive Tech
Technology & Data Platforms
Clinical data & Cross Functional Interactions
Soft Skills

CCDS exam competencies are re-validated periodically in a job analysis called the SCDM Task Analysis Survey.


Item Creation & Review, Exam Launch



High Level Plan



CCDS Item Banking I Lifecycle



Thank You for Your Attention

- Appreciate your interest in clinical data management certifications
- Encourage continuous professional development and learning
- Contact us for further questions and support info@scdm.org



Learning Continuity with elev8 by SCDM



Eva Martin
Education Director


SCDM

Shaping the future of Clinical Data Management and Science Learning

This year, we've reached important milestones

- ✓ Full implementation of the new learning experience platform
- ✓ New strategic available CCDA, CCDM and RBQM Programs and learning support for 20+ GCDMP chapters
- ✓ Over 100 new courses designed around emerging learning trends
- ✓ More than 200 learners onboarded in May 2025
- ✓ Seamless user journey across membership, education, and certification, now with single sign-on

This journey begins with YOU, Your role, Your path, Your pace



Competencies

Skills

Level



We guide your journey in a structured, practical and clear way



Every step is immersive, dynamic, and designed to make education last

📌 Key points that stick

💬 Share, express & connect with peers

🤖 Ask, learn and save time


🎭 Practice real-life situations Key

🧘 Pause and think deeply

🧩 Apply what you've learned




Your learning continues, across formats, moments and connections



Learning is not just a moment. It is a journey

**What was once fragmented is now structured,
immersive, and supports continuous growth**



Where the world's best, bring out the best in you.

Curated learning for everyone
in the CDM industry.

POWERED BY **SCDM**

